UC Davis study: TB vaccine shrinks liver cancer tumors in mice

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A UC Davis Health study found that a single dose of Bacillus Calmette-Guérin, or BCG, the vaccine for tuberculosis, reduced liver tumor burden and extended the survival of mice with liver cancer. The study, published in Advanced Science, is the first to show the promising effects of the vaccine in treating liver cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Jason Chiang and Kyung Sung of the Department of Radiological Sciences at the David Geffen School of Medicine at UCLA and the UCLA Health Jonsson Comprehensive Cancer Center have received a $3.2 million, five-year grant from NCI to develop an artificial intelligence-enhanced imaging platform designed to improve yttrium-90 (Y90) radioembolization planning for patients with liver cancer.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login